- Home
- LGTY vs LRMR Comparison
LGTY vs LRMR Comparison
Compare LGTY & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGTY
- LRMR
- Stock Information
- Founded
- LGTY 1970
- LRMR N/A
- Country
- LGTY United States
- LRMR United States
- Employees
- LGTY N/A
- LRMR N/A
- Industry
- LGTY
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- LGTY
- LRMR Health Care
- Exchange
- LGTY NYSE
- LRMR Nasdaq
- Market Cap
- LGTY 501.6M
- LRMR 426.9M
- IPO Year
- LGTY N/A
- LRMR N/A
- Fundamental
- Price
- LGTY $14.08
- LRMR $3.19
- Analyst Decision
- LGTY Hold
- LRMR Strong Buy
- Analyst Count
- LGTY 1
- LRMR 9
- Target Price
- LGTY N/A
- LRMR $19.44
- AVG Volume (30 Days)
- LGTY 727.6K
- LRMR 630.8K
- Earning Date
- LGTY 02-20-2025
- LRMR 03-13-2025
- Dividend Yield
- LGTY 3.13%
- LRMR N/A
- EPS Growth
- LGTY N/A
- LRMR N/A
- EPS
- LGTY 0.10
- LRMR N/A
- Revenue
- LGTY $101,873,000.00
- LRMR N/A
- Revenue This Year
- LGTY $1.99
- LRMR N/A
- Revenue Next Year
- LGTY $3.46
- LRMR N/A
- P/E Ratio
- LGTY $147.14
- LRMR N/A
- Revenue Growth
- LGTY N/A
- LRMR N/A
- 52 Week Low
- LGTY $8.41
- LRMR $3.01
- 52 Week High
- LGTY $14.20
- LRMR $12.91
- Technical
- Relative Strength Index (RSI)
- LGTY N/A
- LRMR 37.56
- Support Level
- LGTY N/A
- LRMR $3.06
- Resistance Level
- LGTY N/A
- LRMR $3.52
- Average True Range (ATR)
- LGTY 0.00
- LRMR 0.22
- MACD
- LGTY 0.00
- LRMR 0.02
- Stochastic Oscillator
- LGTY 0.00
- LRMR 15.66
About LGTY LOGILITY SUPPLY CHAIN SOLUTIONS INC
Logility Supply Chain Solutions Inc develops enterprise management and supply chain-related software and services. Its Services include Scenario Planning Products, Demand Planning InventoryAI+, Supply, Deployment, Supply Chain Data Management, and Supply Chain Design. The group provides services to various industries such as Food and Beverage Consumer Packaged Goods, Process Manufacturing, Industrial Manufacturing, Chemicals, and others.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.